Healthcare · Drug Manufacturers Specialty Generic · NYSE
Elanco Animal Health (ELAN) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $13.14B, a trailing price-to-earnings ratio of 23.1 and a free-cash-flow yield of 2.2%. Over the most recent reported fiscal year, revenue grew 6.2% and free cash flow per share fell 27.8%. Nama's AI scorecard rates it Hold, 5.5 out of 10. On 12-month momentum it ranks in the middle band of its market.
AI scorecard
Hold · 5.5/10
The sections balance. As of Nov 20, 2026.
Momentum
Middle · +6.2% over 12 months ex. last
Middle fifth of its market on the past year's move.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-21.6%
How far the last close sits under the highest price of the past five years.
Market cap
$13.14B
Trailing P/E
23.1
Price / book
2.0
Price / sales
2.5
FCF yield
2.2%
Dividend yield
—
Gross margin
56.2%
Operating margin
7.6%
Net margin
-2.9%
Revenue growth (YoY)
+6.2%
Revenue growth (3-yr annual)
+2.2%
EPS growth (YoY)
+4.4%
FCF/share growth (YoY)
-27.8%
Beta
1.7
Exchange
NYSE
Sector
Healthcare
Industry
Drug Manufacturers Specialty Generic
ELAN earnings
Next report: Feb 23, 2027 (Q4 2026, EPS estimate $0.17).
Beat the EPS estimate in 4 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Nov 6, 2026
$0.27
$0.20
+35.0%
$1.26B
Q2 2026
Aug 5, 2026
$0.34
$0.27
+25.9%
$1.37B
Q1 2026
May 6, 2026
$0.40
$0.34
+17.6%
$1.37B
Q4 2025
Feb 24, 2026
$0.13
$0.12
+8.3%
$1.14B
ELAN analyst price target
Median target $32.00 from 13 analysts, ranging $25.00 – $35.00.
Nama's AI scorecard currently rates Elanco Animal Health Hold (5.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ELAN's P/E ratio?
Elanco Animal Health trades at a trailing price-to-earnings ratio of 23.1.
When does ELAN report earnings?
Elanco Animal Health's next scheduled report is on Feb 23, 2027. Analysts expect EPS of $0.17.
What is the ELAN price target?
The median analyst price target from 13 analysts is $32.00, with a range of $25.00 – $35.00.
Is ELAN Shariah compliant?
Nama's AAOIFI-style screen reads Elanco Animal Health as Not Shariah Compliant. At least one of the three ratios or the industry test failed.